Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States

Gee, Julianne; Weinbaum, Cindy; Sukumaran, Lakshmi; Markowitz, Lauri E.

doi:10.1080/21645515.2016.1168952

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States

Mar 30 2016
By Gee, Julianne ; Weinbaum, Cindy ; Sukumaran, Lakshmi ; ...
http://dx.doi.org/10.1080/21645515.2016.1168952
Source: Hum Vaccin Immunother. 2016; 12(6):1406-1417.

[PDF-446.81 KB]

English

Details Supporting Files You May Also Like

Details:

Alternative Title:

Hum Vaccin Immunother
Personal Author:

Gee, Julianne ; Weinbaum, Cindy ; Sukumaran, Lakshmi ; Markowitz, Lauri E.

Gee, Julianne ; Weinbaum, Cindy ; Sukumaran, Lakshmi ; Markowitz, Lauri E. Less -
Description:

Quadrivalent human papillomavirus (4vHPV) vaccine was licensed for use in the United States in 2006 and through 2015 was the predominate HPV vaccine used. With the exception of syncope, a known preventable adverse event after any injected vaccination, both pre-licensure and post-licensure 4vHPV safety data have been reassuring with no confirmed safety signals identified. Nine-valent HPV vaccine (9vHPV) was licensed in 2014. This review includes post-licensure 4vHPV safety findings published to date that have informed the US vaccination program; these data will inform US safety monitoring and evaluation for 9vHPV.
Subjects:

[+]

Adverse Drug Reaction Reporting Systems Epidemiological Monitoring Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 Humans Syncope
Source:

Hum Vaccin Immunother. 2016; 12(6):1406-1417.
Pubmed ID:

27029786
Pubmed Central ID:

PMC4964727
Document Type:

Journal Article
Place as Subject:

United States
Volume:

12
Issue:

6
Collection(s):

CDC Public Access
Main Document Checksum:

[+]

urn:sha256:8ba3c009f8b275bdc77ee5b1d8e7bd786e6f63671ecb383c8fec5f0061ac5d33
Download URL:

https://stacks.cdc.gov/view/cdc/60064/cdc_60064_DS1.pdf
File Type:

khvi-12-06-1168952.nxml

xml

More +